NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00721409,Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer,https://clinicaltrials.gov/study/NCT00721409,,COMPLETED,The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer,YES,Breast Cancer,DRUG: PD 0332991|DRUG: letrozole|DRUG: letrozole,"Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1, An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly., Maximum treatment duration (approximately 55 months)|Number of Participants With Treatment-Related Adverse Events at Phase 1, An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly., Maximum treatment duration (approximately 55 months)|Number of Participants With Dose Limiting Toxicities at Phase 1, Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets \<25,000/μL, ANC \<500/μL). 2. Grade 3 neutropenia associated with a documented infection or fever ≥38.5°C. 3. Grade ≥3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by ≥1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count \<50,000/μL; ANC \<1,000/μL; nonhematologic toxicities of Grade ≥3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment., Cycle 2 (4 weeks)|Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment, PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs)., From randomization date to date of first documentation of progression or death (assessed up to 41 months)","Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1, Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions., From Baseline up to end of study (assessed up to 55 months)|Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1, CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging \>= 4 weeks after initial response., From Baseline up to end of study (assessed up to 55 months)|Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1, On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing., Cycle 1 Day 14, and Cycle 2 Day 14|Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1, On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing., Cycle 1 Day 14, and Cycle 2 Day 14|Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1, On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing., Cycle 1 Day 14, and Cycle 2 Day 14|Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1, On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing., Cycle 1 Day 14, and Cycle 2 Day 14|Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1, On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing., Cycle 1 Day 14, and Cycle 2 Day 14|Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1, On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing., Cycle 1 Day 14, and Cycle 2 Day 14|Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1, On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing., Cycle 2 Day 14, Cycle 2 Day 28|Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1, On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing., Cycle 2 Day 14, and Cycle 2 Day 28|Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1, On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing., Cycle 2 Day 14, and Cycle 2 Day 28|Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1, Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (\<) 60 msec(borderline) and greater than or equal to (\>=) 60 msec (prolonged) were summarized., Cycle 1 Day 1 prior to dosing, Cycle 1 Day 14 (2, 4 [prior to meal], 8, 24, 48, and 96 hours after dosing of Palbociclib), Cycle 2 Day 1 and Day 14 (prior to and 4 hours after dosing of letrozole)|Overall Survival (OS) at Phase 2, Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months., From randomization until death (assessed up to 86 months)|Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment, Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions., From randomization up to the end of treatment (approximately 41 months)|Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment, Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as ≥30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as ≥20 mm with conventional techniques or as ≥10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes)., From randomization up to the end of treatment (approximately 41 months)|Duration of Response at Phase 2 - Investigator Assessment, Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST)., From randomization up to the end of treatment (approximately 41 months)|Number of Participants With CBR at Phase 2 - Investigator Assessment, CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST., From randomization up to the end of treatment (approximately 41 months)|Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment, Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization \[or first dose of study medication for non-randomized studies\] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST)., From randomization up to the end of treatment (approximately 41 months)|Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2, The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (""no pain"" or ""does not interfere"") to 10 (""pain as bad as you can imagine"" or ""completely interferes"")., Baseline, End of treatment (approximately 41 months)|Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2, The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 (""no pain"" or ""does not interfere"") to 10 (""pain as bad as you can imagine"" or ""completely interferes"")., Baseline, End of treatment (approximately 41 months)|Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1, Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples., Screening visit (≤ 28 Days prior to dosing)|Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67, Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups., Screening visit (≤ 28 Days prior to dosing)|Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1, Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression \>0 and Negative: any expression=0., Screening visit (≤ 28 Days prior to dosing)|Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2, Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group., Screening visit (≤ 28 Days prior to dosing)|Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2, One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed., Screening visit (≤ 28 Days prior to dosing)|Number of Participants With TEAEs (All Causalities) at Phase 2, AE:any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non-serious AEs.SAE:AE resulting in any of following outcomes/deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience (immediate risk of dying);persistent or significant disability/incapacity;congenital anomaly.Treatment emergent AEs:events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or worsened relative to pre-treatment state.AEs were graded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and coded using Medical Dictionary for Regulatory Activities (MedDRA). Participants with AE of grade 3 or 4 and grade 5 were reported as Grade 3:Severe, Grade 4:Life threatening, Grade 5:Death related to AE., Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)|Number of Participants With Treatment-Related Adverse Events at Phase 2, AE: any untoward medical occurrence in a participant who received study drug. AEs included both serious and non-serious adverse events. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs: events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Treatment related AEs: all AEs with causality related to treatment. Relatedness to drug was assessed by the investigator. AEs were graded according to the CTCAE version 3.0 and coded using the MedDRA. Number of participants with AE of grade 3 or 4 and with AE of grade 5 were reported as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE., Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)",,Pfizer,,FEMALE,"ADULT, OLDER_ADULT",PHASE2,177,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: |Masking: NONE|Primary Purpose: TREATMENT,A5481003|2008-002392-27,2008-09-15,2013-11-29,2017-12-20,2008-07-24,2015-03-19,2019-11-04,"Central Hematology Oncology Medical group Inc., Alhambra, California, 91801, United States|UCLA Hematology/Oncology - Alhambra, Alhambra, California, 91801, United States|CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California, 93309, United States|St. Joseph Heritage Healthcare, Fullerton, California, 92835, United States|UCLA West Medical Pharmacy (Drug Management Only), Los Angeles, California, 90095-1772, United States|UCLA West Medical Pharmacy, Los Angeles, California, 90095-1772, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, 90095-6984, United States|UCLA West Medical Pharmacy, Los Angeles, California, 90095-7349, United States|Drug Management Only: UCLA West Medical Pharmacy, Los Angeles, California, 90095, United States|Drug Management Only, Los Angeles, California, 90095, United States|Regulatory Managment, Los Angeles, California, 90095, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, 90095, United States|TORI -US Central Administration (Regulatory Management), Los Angeles, California, 90095, United States|TORI -US Central Administration, Los Angeles, California, 90095, United States|TORI Central Administration (Regulatory Management), Los Angeles, California, 90095, United States|TORI Central Administration (Regulatory Managment Only), Los Angeles, California, 90095, United States|TRIO-US Central Administration, Los Angeles, California, 90095, United States|UCLA Hematology/Oncology, Los Angeles, California, 90095, United States|UCLA, Hematology/Oncology, Los Angeles, California, 90095, United States|Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles, California, 90095, United States|Central Hematology Oncology Medical Group, Inc, Pasadena, California, 91107, United States|Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California, 90277, United States|Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara, California, 93105, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, 93454, United States|Santa Monica-UCLA Medical Center and Orthopaedic Hospital, Santa Monica, California, 90404, United States|UCLA Hematology Oncology-Santa Monica, Santa Monica, California, 90404, United States|UCLA Hematology/Oncology - Santa Clarita, Valencia, California, 91355, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Duluth, Georgia, 30096, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Lawrenceville, Georgia, 30046, United States|Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care, Snellville, Georgia, 30078, United States|Illinois Cancer Specialists, Chicago, Illinois, 60611, United States|Resurrection Medical Group, Chicago, Illinois, 60657, United States|North Shore Oncology-Hematology Associates, Crystal Lake, Illinois, 60014, United States|North Shore Hematology Oncology, Highland Park, Illinois, 60035, United States|North Shore Oncology-Hematology Associates, Libertyville, Illinois, 60048, United States|North Shore Hematology Oncology, Skokie, Illinois, 60077, United States|Regulatory Office: Comprehensive Cancer Centers of Nevada, Henderson, Nevada, 89014, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, 89052, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, 89074, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89128, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89148, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89169, United States|Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas, 75231, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|Investigational Products Center (IPC), Fort Worth, Texas, 76177, United States|US Oncology Research and Clinical Pharmacy, Fort Worth, Texas, 76177, United States|Virginia Cancer Specialists, PC, Arlington, Virginia, 22205, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, 22031, United States|Virginia Cancer Specialists, PC, Gainesville, Virginia, 20155, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, 20176, United States|Virginia Cancer Specialists, PC, Woodbridge, Virginia, 22191, United States|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, V5Z 4E6, Canada|CSSS Champlain-Charles-Le Moyne Local HS-0054, Greenfield Park, Quebec, J4V 2H1, Canada|Centre Paul Papin, CRLCC, ANGERS Cedex 9, 49933, France|CHD Vendee, La Roche Sur Yon, 85925, France|Gemeinschaftspraxis, Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, 14195, Germany|Gemeinschaftspraxis Haematologie-Onkologie, Dresden, 01307, Germany|Martin-Luther-Universitaet Halle-Wittenberg, Halle/Saale, 06097, Germany|Universitaetsklinik und Poliklinik fuer Gynaekologie, Martin-Luther-Universitaet Halle-Wittenberg, Halle/Saale, 06120, Germany|Nationales Centrum fuer Tumorerkrankungen, Heidelberg, 69120, Germany|Frauenaerzte Pruener Gang Abts & Partner, Kiel, 24103, Germany|Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Universitaetsklinik Mainz, Mainz, 55101, Germany|Onkolog. Gemeinschaftspraxis, Muenchen, 80335, Germany|Frauenklinik vom Roten Kreuz, Muenchen, 80637, Germany|Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen, Muenchen, 81675, Germany|Mutterhaus der Borromaeerinnen, Innere Medizin I, Trier, 54290, Germany|Szent Margit Korhaz, Onkologia, Budapest, 1032, Hungary|Orszagos Onkologiai Intezet, Kemoterapia B, Budapest, 1122, Hungary|Fovarosi Onkormanyzat Uzsoki Utcai Korhaz, Budapest, 1145, Hungary|Petz Aladar Megyei Oktato Korhaz, Onkoradiologia, Gyor, 9023, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz és Egyetemi Oktato Korhaz, Onkologia, Miskolc, 3526, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es, Nyiregyhaza, 4400, Hungary|Markusovszky Egyetemi Oktatokorhaz, Onkoradiologiai Osztaly, Szombathely, 9700, Hungary|Bon Secours Hospital, Cork, Ireland|St. James's Hospital, Dublin 8, Ireland|St. Vincent's University Hospital, Dublin, 4, Ireland|Mater Misericordiae University Hospital, Dublin, 7, Ireland|Mater Private Hospital, Dublin, 7, Ireland|Divisione Oncologia Medica Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, Meldola, FC, 47014, Italy|M.O. di Oncologia - Azienda USL di Rimini - Ospedale ""Cervesi"", Cattolica, 47841, Italy|Ospedale Civile di Faenza Centro Oncologico, Faenza, RA, 48018, Italy|Unita' Operativa di Oncologia, Ospedale Civile di Lugo, Lugo, RA, 48022, Italy|Ospedale Civile di Ravenna, Ravenna, 48100, Italy|Azienda Unita Sanitaria Locale di Rimini, U.O. di Oncologia ed Oncoematologia Ospedale degli Infermi, Rimini, 47900, Italy|Ospedale Villa San Pietro, Roma, 00189, Italy|National Cancer Center, Center for Breast Cancer, Goyang-si, Gyeonggi-do, 10408, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Samsung Medical Center, Seoul, 135-710, Korea, Republic of|Federal State Budgetary Scientific Institution, Moscow, 115478, Russian Federation|Pyatigorsk Oncology Center, Pyatigorsk, 357502, Russian Federation|State Budgetary Healthcare Institution ""Samara Regional Clinical Oncology Dispensary"", Samara, 443031, Russian Federation|Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic, Ufa, 450054, Russian Federation|Department of Oncotherapy, National Hospital, Bloemfontein, 9301, South Africa|Eastleigh Breast Care Centre, Pretoria, 0041, South Africa|Ico-Hospitalet, Hospitalet de Llobregat, Barcelona, 08907, Spain|Hospital General Universitario Vall D'Hebron, Barcelona, 08035, Spain|Centro Oncologico de Galicia, La Coruña, 15009, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, 41013, Spain|Department of Oncology and Medical Radiology, SI ""DMA of MOH, Ukraine, ""MI ""Dnipropetrovsk City, Dnipropetrovsk, 49102, Ukraine|Municipal Treatment-and-Prophylactic Institution 'Donetsk City Oncological Dispensary' Radiology dep, Donetsk, 83087, Ukraine|Municipal clinical treatment-and-propyilactic institution ""Donetsk regional oncology center',, Donetsk, 83092, Ukraine|Kyiv City Clinical Oncologic Center, Kyiv, 03115, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Centre, Lviv, 79031, Ukraine",
